Abstract. It has been suggested that metabolic syndrome (MetS) overlaps prediabetes and type 2 diabetes and that it is not necessary to consider it as a separate clinical entity. In the present study, patients with normoglycemia and dysglycemia were compared in terms of MetS frequency and MetS criteria characteristics, in order to test the appropriateness of considering MetS as a condition independent of prediabetes and type 2 diabetes. A total of 1222 (801 females, 401 males, mean age: 51.50 ± 11.73 y) consecutive patients attending Internal Medicine outpatient clinics were included. Cases were assigned into two groups: patients with normoglycemia (fasting plasma glucose <100 mg/dl, n = 555) or dysglycemia (fasting plasma glucose ≥100 mg/dl and/or receiving antidiabetic treatment, n = 667). Groups were compared in terms of MetS frequency and MetS criteria characteristics. A 2-hour oral glucose tolerance test was administered to the normoglycemia group. In addition, patients with MetS were assigned into two groups: patients with normoglycemia and dysglycemia. These two groups were also compared in terms of MetS criteria characteristics. Adult Treatment Panel III criteria were used for the diagnosis of MetS. The overall frequency of MetS was 52.2%. MetS was found in 72.7% of patients with dysglycemia and 27.6% of patients with normoglycemia (p = 0.001). Mean systolic and diastolic blood pressure, waist circumference and triglyceride levels were similar between normoglycemic and dysglycemic MetS patients (p>0.05). Impaired glucose tolerance was higher among normoglycemic MetS patients compared to normoglycemic patients without MetS (13.7% vs. 6.5%, p = 0.006). In conclusion, although MetS is a well known risk factor for type 2 diabetes, our results support that it is a separate entity independent of prediabetes and type 2 diabetes mellitus.
METABOLIC syndrome (MetS) is a cluster of risk factors including abdominal obesity, high blood pressure, dysglycemia and dyslipidemia [1] . Among MetS parameters, dyslipidemia and hypertension are frequently seen in patients with type 2 diabetes [2] [3] [4] . It is suggested that there is an overlapping between MetS and prediabetes or type 2 diabetes and that MetS need not to be considered as a separate clinical entity [5] . On the other hand, when the diagnostic criteria of guidelines are taken into consideration, MetS can be quite frequent among patients with normal glucose levels [6] . In the present study, patients with normoglycemia and dysglycemia were compared in terms of MetS frequency and MetS criteria characteristics, in order to test whether considering MetS as a separate clinical entity independent of prediabetes and type 2 diabetes is an appropriate approach.
Materials and Methods
A total of 1223 consecutive patients ≥20 years old attending Internal Medicine outpatient clinics of Goztepe Training and Research Hospital were included in this study. Study protocol was approved by local ethics committee and the study was conducted in accordance with the principles of Helsinki Declaration.
Inclusion criteria
Patients with biochemical analyses results and wishing to give informed consent.
Exclusion criteria
Pregnancy, ascites or abdominal mass, presence of a severe cardiac, liver or renal disease.
Eligible patients were assigned into two groups: normoglycemic patients (blood glucose <100 mg/dl) and patients with dysglycemia (blood glucose ≥100 mg/dl and/or receiving antidiabetic treatment). Two groups were compared in terms of MetS frequency and MetS criteria characteristics. In addition, MetS patients were also categorized as normoglycemic patients and patients with dysglycemia; these two groups were also compared in terms of MetS characteristics. Patients with dysglycemia were evaluated in both groups as either impaired fasting glucose (IFG, fasting plasma glucose 100-125 mg/dl) or diabetes mellitus (DM, fasting plasma glucose ≥126 mg/dl) [7] .
Patients with normoglycemia received a 2-hour oral glucose tolerance test (OGTT) with 75 g of glucose. WHO protocol was used for OGTT [8] . A blood glucose level between 140 mg/dl and 199 mg/dl at two hours was defined as impaired glucose tolerance (IGT) [7] . Normoglycemic patients with or without MetS were compared in terms of IGT frequency.
Following criteria proposed by National Cholesterol Education Program Adult Treatment Panel (ATP) III were used for the diagnosis of MetS: blood pressure ≥130/85 mmHg (or use of antihypertensive medication); fasting plasma glucose ≥100 mg/dl (or use of antidiabetic medication); fasting triglycerides ≥150 mg/ dl; high density lipoprotein (HDL) cholesterol <40 mg/ dl (men) or <50 mg/dl (women); waist circumference >102 cm (men) or >88 cm (women) [9] . At least three of the above criteria were required for the diagnosis of MetS.
Anthropometric and biochemical measurements
Sitting blood pressure was measured in both arms after at least 10 minutes of rest with an appropriate mercury sphygmomanometer using the Phase I and Phase V Korotkoff sounds. A second measurement was made after at least 3 minutes in the arm with the highest measurement. The mean of two measurements was used for systolic and diastolic blood pressures. The waist circumference was measured at the plane between anterior superior iliac spines and lower costal margins at the narrowest part of the waistline while the patient was standing and during slight expiration. Venous blood samples were obtained following 12 hours of fasting; glucose and triglycerides levels were measured by enzymatic methods and HDL cholesterol was measured by direct method.
Statistical analyses
SPSS (Statistical Package for Social Sciences) for Windows 10.0 software was used for the statistical analyses. In addition to descriptive statistics (mean, standard deviation), One-way Anova test was used for the comparisons of quantitative data and for the intergroup comparison of parameters with normal distribution. Tukey HDS test was used for the detection of the group responsible for the difference. For the intergroup comparisons of parameters without a normal distribution, Kruskal Wallis test was used; and Mann Whitney U test was used for the detection of the differing group. Chi-square test was used for the comparisons between qualitative data. The results were evaluated at a significance level of 0.05 with 95% confidence intervals.
Results
A total of 1223 cases were included in the study (801 females, 401 males, mean age: 51.50 ± 11.73 y). Normoglycemia group and dysglycemia group consisted of 555 and 667 patients, respectively. Among cases with dysglycemia, 28.6% had DM and 71.4% had IFG.
Demographic, anthropometric and biochemical characteristics of patients are depicted in Table 1 and 2. Sex distribution and cigarette smoking were similar among groups (p>0.05). The overall frequency of MetS was 52.2%. MetS was found in 72.7% of patients with dysglycemia and 27.6% of patients with normoglycemia (p = 0.001). The mean values for age, systolic blood pressure, diastolic blood pressure, waist circumference and triglyceride levels were higher (p = 0.001 for all) and mean HDL level was lower (p = 0.001) in patients with dysglycemia compared to normoglycemic patients.
Demographic and MetS characteristics of MetS cases are given in Table 3 and 4. Among MetS cases, 76% had dysglycemia and 24% had normoglycemia. MetS patients with dysglycemia were older and had higher HDL cholesterol levels and higher mean number of MetS criteria present compared to normoglycemic MetS patients (p = 0.01 for all), on the other hand, these two groups were similar in terms of mean systolic blood pressure, diastolic blood pressure, waist circumference and triglyceride levels (p>0.05). IGT was present in 8.4% of patients with normoglycemia. IGT was more frequent among normoglycemic patients with MetS compared to normoglycemic patients without MetS (13.7% vs. 6.5%, p = 0.006) ( Table 5) .
Discussion
In the present study, about three quarters of patients with dysglycemia had MetS, supporting the association of MetS with prediabetes and type 2 diabetes. On the other hand, the presence of MetS in about one quarter of normoglycemic and non-diabetic patients suggests that MetS is an important cluster of risk factors, not only limited to the results of an impaired carbohydrate metabolism or an association with prediabetes/type 2 diabetes.
MetS is a important public health problem and its prevalence is increasing globally [10] . In the United States of America, according to the screening of NHANES III, MetS frequency was found to be 23.7% in adults 20 years old or older (23.4% and 24% in females and males, respectively) [11] . In that study, the prevalence increased from 6.7% among participants aged 20 through 29 years to 43.5% and 42.0% for participants aged 60 through 69 years and aged at least 70 years, respectively. The prevalence of MetS in Europe has been found similar to that in United States of America [12] . The prevalence of the MetS among Asian population is lower than those reported in western populations [13, 14] . Arai H [15] et al. reported that the prevalence of MetS in the general Japanese population was 7.8% (1.7% and 12.1% in females and males, respectively). However, when they applied the criteria of ATP III, the incidence was about 3-fold higher. Furthermore, it is claimed that with a lower waist circumference cutoff, the prevalence of the MetS in Asian population is comparable to that in Western populations [16] .
In Turkey, the frequency of MetS is very high and on the increase [17, 18] . Kozan et al. [17] reported a prevalence rate for MetS of 33.9% (39.6% and 28.0% in females and males, respectively). In that study, the frequency of MetS was 54.7% between 50-59 years of age (67.9% and 41.1% in females and males, respectively). In the present study, the frequency of MetS was 52.2% (72.3% and 27.7% in females and males, respectively). Although our results are higher than those in other area including United States of America, Japan and European countries, data are comparable to those reported for Turkish population. In addition, the high mean age of the patients (51.50 ± 11.73) we studied can account for the high frequency of MetS in our study.
MetS is a recently described clinical condition, which has been described according to different criteria by different organizations [9, 12, [19] [20] [21] . It has been suggested that MetS overlaps prediabetes and type 2 diabetes and that it is not necessary to consider it as a separate clinical entity [5] . On the other hand, normoglycemic individuals can frequently be diagnosed with MetS according to the criteria of certain organizations. For example, according to the criteria recommended by International Diabetes Federation and ATP III [9, 19] , in a patient with abdominal obesity, two of the criteria other hyperglycemia (high blood pressure, high level of triglycerides, low HDL) is sufficient to establish the diagnosis of MetS. High blood pressure and triglycerides and low HDL have been shown to be associated with insulin resistance [22] . These findings raise the question whether it is convenient to consider MetS as a clinical entity independent of prediabetes and diabetes. The present study has tested this hypothesis. For this aim, a randomly selected 1222 patients were assigned into two groups: normoglycemic patients (fasting plasma glucose <100 mg/dl) and patients with dysglycemia (fasting plasma glucose ≥100 mg/dl and/or receiving antidiabetic treatment). Then these two groups were compared in terms of MetS criteria and MetS frequency. Patients with dysglycemia had higher systolic and diastolic blood pressure, waist circumference and triglyceride levels and lower HDL cholesterol levels, compared to normoglycemics. Three quarters of patients with dysglycemia and one quarter of normoglycemic patients had MetS. These findings may be deemed as expected because it is known that patient with diabetes mellitus may concomitantly have risk factors such as hypertension, abdominal obesity and dyslipidemia (high triglycerides and/or low HDL cholesterol) [2, 23] . Also in our study, when we sub grouped the patients with dysglycemia as patients with IFG and DM and compared them with normoglycemics, we found that systolic and diastolic blood pressure, triglyceride levels and waist circumference was increasing and HDL cholesterol levels were decreasing in parallel with the increasing degree of glycemic impairment, supporting the abovementioned association.
The similarity of blood pressure, waist circumference and triglycerides levels among normoglycemic and dysglycemic MetS patients suggest that development of MetS is independent of the level of glycemia. As comparing MetS cases is the comparison of two groups selected according to the number of certain criteria, comparing absolute values of parameters may give biased results. Because, the presence of two more criteria in patients with IFG or DM is sufficient for the diagnosis of MetS according to ATP III criteria. For normoglycemics however, at least three of the criteria are required for them to be categorized as MetS [9] . Possibly, this may be accounted for the lower HDL cholesterol levels in normoglycemic MetS patient compared to patients with IFG and DM, which was contrary to what was expected. In fact, when all cases are taken into consideration, HDL cholesterol was higher in normoglycemics compared to patients with IFG and DM.
In the present study, 8.4% of patients with normoglycemia had IGT. IGT was significantly more frequent among normoglycemic patients with MetS compared to patients without MetS, suggesting that MetS cases should be evaluated by OGTT, even their fasting glucose levels are normal. However, the 132 patients who still remain normoglycemic after the results of fasting glucose and OGTT levels were fulfilling MetS criteria. This supports the idea that considering MetS as an independent clinical condition of prediabetes and diabetes would be convenient. Of course, long term follow-ups allowing to evaluate the rate of prediabetes or type 2 diabetes development in these patients would better clarify the issue.
The present study is not a population-based prevalence study. Therefore, our results can not be generalized for population. The other drawback of our study is that insulin resistance was not evaluated.
In conclusion, our results support that MetS is a risk factor for diabetes but it is a separate entity from type 2 diabetes and prediabetes; just as it is a risk factor for cardiovascular disease but it is not a cardiovascular disease equivalent.
